BREAK THROUGH

BREAK
THROUGH

Embrace the Challenge with Ono

Ono’s Strengths & Characteristics Ono’s Strengths & Characteristics

Ono’s Strengths & Characteristics

We are an R&D-focused pharmaceutical company that continues striving to produce new drugs for patients worldwide.
R&D R&D

R&D

We respond to unmet medical needs by collaborating with international experts in the creation of new drugs.
Social Responsibility Social Responsibility

Social Responsibility

Our Sustainable Management Policy, formulated in view of the next 100 years.

Corporate Slogan

New drugs are created by overcoming many challenges and failures. Our corporate slogan, “BREAK THROUGH - Embrace the Challenge with ONO -,” expresses our belief that tackling new challenges will lead to a brighter future, and we will keep striving tirelessly toward making that a reality.

Corporate Slogan
  • more R & D

    Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate

  • more R & D

    Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of OPDIVO for the Treatment of Unresectable Anaplastic Thyroid Cancer

  • more R & D

    Bristol Myers Squibb Announces OPDIVO® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

  • more R & D

    Ono Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

  • more R & D

    Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)

View Press Releases

Corporate Report 2025

Learn More
Corporate Report